Davita Inc vs VanEck Junior Gold Miners — how do they compare? Davita Inc trades at $182.14 (market cap $11.38B), while VanEck Junior Gold Miners trades at $119.58. Which is the better fit depends on your goals.
| DVA | GDXJ | |
|---|---|---|
Market Cap | $11.38B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $240.96 | $156.19 |
52-Week Low | $103.87 | $71.22 |
Enterprise Value | $24.10B | — |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $180.25, down 1.87% amid mixed signals. The stock shows strong earnings momentum with three consecutive quarterly beats (Q4 2025-Q2 2026) but faces margin pressure. Technical indicators are conflicted with a bullish overall signal but bearish moving averages. Revenue growth remains steady, climbing from $11.6B in 2022 to $13.6B in 2025, though net income margin fluctuated between 4.82% and 7.3% over the same period.
The outlook is cautiously optimistic with a $232.25 consensus price target offering 29% upside. Key risks include reimbursement pressure and high debt levels (debt-to-asset ratio of 65.55% in 2025). Analyst sentiment leans neutral (56.52% Hold) despite recent earnings strength, reflecting concerns about payer mix and margin sustainability.
GDXJ, the VanEck Junior Gold Miners ETF, trades at $119.18, up 0.34% on the day, with a bullish technical signal driven by moving averages but tempered by overbought oscillators. Recent news highlights institutional selling and underperformance versus peers, while the ETF's composition shows less small-cap exposure than advertised. Key support lies at $118, with resistance at $120.
The outlook is mixed: bullish momentum persists near-term, but high RSI readings and negative sentiment from articles like Seeking Alpha (2026-06-24) suggest caution. Risks include gold price volatility and Federal Reserve policy shifts, while institutional activity, such as Amundi's 50.5% stake reduction (Defense World, 2026-08-06), indicates skepticism.
Trailing returns across standard periods
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →GDXJ provides exposure to small and mid-cap companies in the global gold and silver mining industry. It focuses on 'junior' miners involved in exploration and early production, featuring 2026 leaders like Pan American Silver and Coeur Mining.
Read more on GDXJ →